Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib + Nivolumab + Ipilimumab in Renal Cell Carcinoma
NCT04518046Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitravatinib in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Mirati Therapeutics. Primary endpoint: Frequency of patients experiencing treatment-emergent Adverse Events at 12 months. Started Aug 2020; status: completed.
02
Drugs
sitravatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04518046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518046.